1 |
SIGMAR1
| 2件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
2 |
CD52
| - | D02802
D02802
|
Alemtuzumab
| 22件: 13 13, 15, 19, 20, 36, 43, 44, 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326 |
3 |
TNFSF13B
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | D03068
D03068
|
Belimumab
| 13件: 11 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 |
4 |
TNFSF13B
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | D09704
D09704
|
Atacicept
| 4件: 13 13, 46, 49, 66 |
5 |
CYSLTR1
| 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
6 |
CYSLTR1
| 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction | D08229
D08229
|
Montelukast
| 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
7 |
CA5B
| 2件: Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| 8件: 13 13, 86, 90, 115, 154, 155, 225, 230 |
8 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
9 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
10 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
11 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D03654
D03654
|
Darifenacin
| 2件: 6 6, 13 |
12 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08522
D08522
|
Solifenacin
| 3件: 6 6, 13, 53 |
13 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
14 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
15 |
CHRNA1
| 2件: Virion - Lyssavirus Virion - Lyssavirus, Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
16 |
CHRNA2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
17 |
CHRNA3
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
18 |
CHRNA4
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
19 |
CHRNA5
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
20 |
CHRNA7
| 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
21 |
CHRNB1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
22 |
CHRNB2
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
23 |
CHRNB3
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
24 |
CHRNB4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
25 |
CHRND
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
26 |
CHRNE
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
27 |
CHRNG
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
28 |
CLCN2
| 1件: Mineral absorption Mineral absorption | D04790
D04790
|
Lubiprostone
| 3件: 13 13, 290, 299 |
29 |
CNR1
| 4件: Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D00306
D00306
|
Dronabinol
| 8件: 2 2, 8, 13, 36, 46, 96, 271, 298 |
30 |
CNR1
| 4件: Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D05099
D05099
|
Nabilone
| 3件: 6 6, 13, 127 |
31 |
CNR1
| 4件: Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D10915
D10915
|
Cannabidiol
| 20件: 2 2, 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
32 |
CNR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00306
D00306
|
Dronabinol
| 6件: 13 13, 36, 46, 96, 271, 298 |
33 |
CNR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05099
D05099
|
Nabilone
| 2件: 13 13, 127 |
34 |
CNR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10915
D10915
|
Cannabidiol
| 17件: 13 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
35 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
36 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
37 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
38 |
ADORA3
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
39 |
CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235
D03235
|
Filgrastim
| 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
40 |
CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03247
D03247
|
Lenograstim
| 7件: 2 2, 13, 16, 18, 19, 57, 65 |
41 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08560
D08560
|
Tamsulosin
| 1件: 13 13 |
42 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08560
D08560
|
Tamsulosin
| 1件: 13 13 |
43 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01965
D01965
|
Silodosin
| 2件: 6 6, 13 |
44 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07124
D07124
|
Alfuzosin
| 1件: 13 13 |
45 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08560
D08560
|
Tamsulosin
| 1件: 13 13 |
46 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
47 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
48 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
49 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
50 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
51 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
52 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
53 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
54 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
55 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02147
D02147
|
Salbutamol
| 12件: 3 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 |
56 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07713
D07713
|
Clenbuterol
| 5件: 1 1, 2, 6, 13, 256 |
57 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08092
D08092
|
Isoxsuprine
| 1件: 13 13 |
58 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D09535
D09535
|
Mirabegron
| 4件: 6 6, 13, 53, 226 |
59 |
CYP17A1
| 6件: Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Cortisol synthesis and secretion, Cushing syndrome | D00351
D00351
|
Ketoconazole
| 3件: 8 8, 13, 75 |
60 |
DDC
| 9件: Tyrosine metabolism Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism | D00558
D00558
|
Carbidopa
| 7件: 6 6, 13, 17, 90, 140, 164, 201 |
61 |
DHFR
| 5件: One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
62 |
DHODH
| 3件: Pyrimidine metabolism Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors | D10172
D10172
|
Teriflunomide
| 3件: 13 13, 25, 26 |
63 |
NQO1
| 7件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D08682
D08682
|
Warfarin
| 11件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91 |
64 |
DNMT1
| 3件: Cysteine and methionine metabolism Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer | D03665
D03665
|
Decitabine
| 3件: 13 13, 60, 63 |
65 |
DNMT3A
| 3件: Cysteine and methionine metabolism Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer | D03665
D03665
|
Decitabine
| 3件: 13 13, 60, 63 |
66 |
DNMT3B
| 3件: Cysteine and methionine metabolism Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer | D03665
D03665
|
Decitabine
| 3件: 13 13, 60, 63 |
67 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01745
D01745
|
Domperidone
| 5件: 6 6, 13, 17, 51, 230 |
68 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07868
D07868
|
Domperidone
| 5件: 6 6, 13, 17, 51, 230 |
69 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08456
D08456
|
Quetiapine
| 2件: 6 6, 13 |
70 |
ABAT
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
71 |
S1PR1
| 3件: FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10001
D10001
|
Fingolimod
| 3件: 13 13, 14, 156 |
72 |
S1PR1
| 3件: FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| 3件: 13 13, 96, 97 |
73 |
S1PR1
| 3件: FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D11215
D11215
|
Ponesimod
| 1件: 13 13 |
74 |
S1PR1
| 3件: FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D11460
D11460
|
Siponimod
| 2件: 13 13, 50 |
75 |
S1PR3
| 2件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| 3件: 13 13, 96, 97 |
76 |
ELANE
| 3件: Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Transcriptional misregulation in cancer, Systemic lupus erythematosus | D03788
D03788
|
Sivelestat
| 3件: 13 13, 85, 96 |
77 |
DHFR2
| 5件: One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
78 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00105
D00105
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
79 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00185
D00185
|
Estriol
| 2件: 13 13, 227 |
80 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00554
D00554
|
Ethinylestradiol
| 4件: 13 13, 46, 49, 299 |
81 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01986
D01986
|
Estriol
| 2件: 13 13, 227 |
82 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00105
D00105
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
83 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00185
D00185
|
Estriol
| 2件: 13 13, 227 |
84 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01986
D01986
|
Estriol
| 2件: 13 13, 227 |
85 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D01968
D01968
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
86 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D08689
D08689
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
87 |
FGFR2
| 13件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, Prostate cancer, Gastric cancer, Central carbon metabolism in cancer | D05338
D05338
|
Palifermin
| 5件: 13 13, 36, 38, 39, 65 |
88 |
NCSTN
| 2件: Notch signaling pathway Notch signaling pathway, Alzheimer disease | D09010
D09010
|
Tarenflurbil
| 1件: 13 13 |
89 |
CA14
| 2件: Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| 8件: 13 13, 86, 90, 115, 154, 155, 225, 230 |
90 |
MTOR
| 51件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D00753
D00753
|
Sirolimus
| 40件: 2 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 |
91 |
MTOR
| 51件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D06068
D06068
|
Temsirolimus
| 1件: 13 13 |
92 |
GABBR1
| 7件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction | D00241
D00241
|
Baclofen
| 8件: 2 2, 10, 13, 18, 65, 70, 149, 206 |
93 |
GABBR1
| 7件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction | D08861
D08861
|
Arbaclofen Placarbil
| 1件: 13 13 |
94 |
GABBR1
| 7件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction | D09791
D09791
|
Arbaclofen
| 2件: 13 13, 206 |
95 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
96 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
97 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
98 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
99 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
100 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
101 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
102 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
103 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
104 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
105 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
106 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
107 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
108 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
109 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
110 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
111 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
112 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
113 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
114 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
115 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
116 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
117 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
118 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
119 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
120 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
121 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
122 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
123 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
124 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
125 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
126 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
127 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
128 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
129 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
130 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
131 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
132 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
133 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
134 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
135 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
136 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
137 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
138 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
139 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
140 |
GAD1
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
141 |
GAD2
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
142 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
143 |
GHRHR
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D08523
D08523
|
Somatorelin
| 2件: 13 13, 78 |
144 |
GLP1R
| 3件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion | D09889
D09889
|
Dulaglutide
| 2件: 13 13, 299 |
145 |
GRIA1
| 14件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
146 |
GRIA2
| 15件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
147 |
GRIA3
| 13件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
148 |
GRIA4
| 10件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
149 |
GRIK1
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
150 |
GRIK2
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
151 |
GRIK3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
152 |
GRIK4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
153 |
GRIK5
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
154 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
155 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
156 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
157 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
158 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
159 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
160 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
161 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
162 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
163 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
164 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
165 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
166 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
167 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
168 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
169 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
170 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
171 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
172 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
173 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
174 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
175 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
176 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
177 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
178 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
179 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292
D00292
|
Dexamethasone
| 22件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
180 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407
D00407
|
Methylprednisolone
| 44件: 13 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
181 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472
D00472
|
Prednisolone
| 40件: 13 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
182 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473
D00473
|
Prednisone
| 43件: 13 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
183 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05000
D05000
|
Methylprednisolone hemisuccinate
| 7件: 13 13, 49, 50, 51, 53, 97, 211 |
184 |
HCRTR1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10082
D10082
|
Suvorexant
| 1件: 13 13 |
185 |
HCRTR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10082
D10082
|
Suvorexant
| 1件: 13 13 |
186 |
HMGCR
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D00434
D00434
|
Simvastatin
| 21件: 6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 |
187 |
HMGCR
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D07474
D07474
|
Atorvastatin
| 19件: 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 |
188 |
HMGCR
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D08410
D08410
|
Pravastatin
| 9件: 13 13, 46, 49, 67, 79, 96, 164, 265, 333 |
189 |
HPRT1
| 4件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D08603
D08603
|
Tioguanine
| 2件: 13 13, 37 |
190 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00300
D00300
|
Diphenhydramine
| 8件: 11 11, 13, 49, 51, 70, 86, 222, 256 |
191 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00364
D00364
|
Loratadine
| 4件: 13 13, 46, 89, 98 |
192 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03535
D03535
|
Clemastine
| 1件: 13 13 |
193 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03693
D03693
|
Desloratadine
| 1件: 13 13 |
194 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D07662
D07662
|
Cetirizine
| 4件: 13 13, 28, 35, 300 |
195 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D07803
D07803
|
Dexchlorpheniramine
| 2件: 13 13, 49 |
196 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D07958
D07958
|
Fexofenadine
| 2件: 13 13, 46 |
197 |
HRH2
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion | D00422
D00422
|
Ranitidine
| 2件: 13 13, 65 |
198 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D00274
D00274
|
Cisapride
| 1件: 13 13 |
199 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D02092
D02092
|
Cisapride
| 1件: 13 13 |
200 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D08456
D08456
|
Quetiapine
| 2件: 6 6, 13 |
201 |
HTR3A
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00274
D00274
|
Cisapride
| 1件: 13 13 |
202 |
HTR3A
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D02092
D02092
|
Cisapride
| 1件: 13 13 |
203 |
HTR4
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse | D00274
D00274
|
Cisapride
| 1件: 13 13 |
204 |
HTR4
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse | D02092
D02092
|
Cisapride
| 1件: 13 13 |
205 |
HTR4
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse | D09205
D09205
|
Prucalopride
| 3件: 13 13, 51, 96 |
206 |
IFNAR1
| 18件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
207 |
IFNAR1
| 18件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
208 |
IFNAR1
| 18件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
209 |
IFNAR1
| 18件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
210 |
IFNAR2
| 17件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
211 |
IFNAR2
| 17件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
212 |
IFNAR2
| 17件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
213 |
IFNAR2
| 17件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
214 |
IL1A
| 21件: MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
215 |
IL1B
| 44件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
216 |
IL1R1
| 13件: MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis | D02934
D02934
|
Anakinra
| 18件: 2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 |
217 |
IL2RA
| 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D03639
D03639
|
Daclizumab
| 8件: 13 13, 56, 60, 65, 97, 107, 283, 284 |
218 |
IL6
| 51件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
219 |
IL6R
| 12件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | D02596
D02596
|
Tocilizumab
| 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
220 |
IL6R
| 12件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | D11079
D11079
|
Satralizumab
| 3件: 11 11, 13, 86 |
221 |
IL10
| 22件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
222 |
IL17A
| 6件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | D09967
D09967
|
Secukinumab
| 8件: 13 13, 37, 41, 46, 107, 160, 269, 271 |
223 |
IMPDH1
| 4件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D00752
D00752
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
224 |
IMPDH1
| 4件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D05096
D05096
|
Mycophenolic acid
| 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
225 |
IMPDH2
| 4件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D00752
D00752
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
226 |
IMPDH2
| 4件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D05096
D05096
|
Mycophenolic acid
| 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
227 |
ITGA4
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D06590
D06590
|
Firategrast
| 1件: 13 13 |
228 |
ITGA4
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D06886
D06886
|
Natalizumab
| 6件: 13 13, 15, 25, 46, 63, 96 |
229 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00075
D00075
|
Testosterone
| 8件: 1 1, 2, 3, 13, 60, 76, 78, 113 |
230 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D06087
D06087
|
Testosterone undecanoate
| 2件: 13 13, 60 |
231 |
ITGAL
| 12件: Rap1 signaling pathway Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis | D03959
D03959
|
Efalizumab
| 9件: 11 11, 13, 37, 46, 49, 53, 61, 95, 96 |
232 |
KCNA4
| 2件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome | D04127
D04127
|
Dalfampridine
| 5件: 3 3, 4, 6, 13, 14 |
233 |
KCNC3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D04127
D04127
|
Dalfampridine
| 2件: 13 13, 14 |
234 |
KCND2
| 1件: Serotonergic synapse Serotonergic synapse | D04127
D04127
|
Dalfampridine
| 2件: 13 13, 14 |
235 |
KCND3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D04127
D04127
|
Dalfampridine
| 2件: 13 13, 14 |
236 |
KCNJ11
| 3件: Insulin secretion Insulin secretion, GnRH secretion, Type II diabetes mellitus | D00294
D00294
|
Diazoxide
| 2件: 13 13, 193 |
237 |
CA13
| 2件: Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| 8件: 13 13, 86, 90, 115, 154, 155, 225, 230 |
238 |
KIT
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
239 |
KIT
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D10229
D10229
|
Masitinib
| 6件: 2 2, 5, 6, 13, 46, 96 |
240 |
LTB
| 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis | D08866
D08866
|
Baminercept
| 4件: 13 13, 46, 53, 97 |
241 |
MC2R
| 5件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome | D00146
D00146
|
Corticotropin
| 12件: 2 2, 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222 |
242 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D03822
D03822
|
Rivastigmine
| 3件: 5 5, 6, 13 |
243 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D07869
D07869
|
Donepezil
| 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
244 |
MTNR1A
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| 12件: 6 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202 |
245 |
MTNR1B
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| 12件: 6 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202 |
246 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05353
D05353
|
Pantoprazole
| 2件: 13 13, 65 |
247 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
248 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05353
D05353
|
Pantoprazole
| 2件: 13 13, 65 |
249 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
250 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
251 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05312
D05312
|
Oxycodone
| 5件: 6 6, 13, 70, 226, 298 |
252 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08144
D08144
|
Loperamide
| 2件: 13 13, 97 |
253 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| 11件: 13 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
254 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05312
D05312
|
Oxycodone
| 4件: 13 13, 70, 226, 298 |
255 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D08144
D08144
|
Loperamide
| 2件: 13 13, 97 |
256 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05113
D05113
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
257 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05312
D05312
|
Oxycodone
| 5件: 6 6, 13, 70, 226, 298 |
258 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D08144
D08144
|
Loperamide
| 2件: 13 13, 97 |
259 |
APH1A
| 2件: Notch signaling pathway Notch signaling pathway, Alzheimer disease | D09010
D09010
|
Tarenflurbil
| 1件: 13 13 |
260 |
PDCD1
| 3件: Cell adhesion molecules Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10316
D10316
|
Nivolumab
| 12件: 13 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 |
261 |
PDE3A
| 6件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
262 |
PDE3B
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
263 |
PDE4A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
264 |
PDE4A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01783
D01783
|
Rolipram
| 2件: 8 8, 13 |
265 |
PDE4B
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
266 |
PDE4B
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01783
D01783
|
Rolipram
| 2件: 8 8, 13 |
267 |
PDE4C
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
268 |
PDE4C
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01783
D01783
|
Rolipram
| 2件: 8 8, 13 |
269 |
PDE4D
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
270 |
PDE4D
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01783
D01783
|
Rolipram
| 2件: 8 8, 13 |
271 |
PDGFRA
| 20件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
272 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D00182
D00182
|
Norethisterone
| 4件: 13 13, 46, 49, 299 |
273 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D00950
D00950
|
Levonorgestrel
| 1件: 13 13 |
274 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D00951
D00951
|
Medroxyprogesterone acetate
| 8件: 13 13, 35, 46, 49, 50, 51, 60, 107 |
275 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D01217
D01217
|
Dydrogesterone
| 1件: 13 13 |
276 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D07222
D07222
|
Nomegestrol
| 1件: 13 13 |
277 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D08281
D08281
|
Nomegestrol acetate
| 1件: 13 13 |
278 |
S1PR5
| 2件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| 3件: 13 13, 96, 97 |
279 |
S1PR5
| 2件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D11460
D11460
|
Siponimod
| 2件: 13 13, 50 |
280 |
PPARG
| 11件: PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08378
D08378
|
Pioglitazone
| 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
281 |
PPP3CA
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
282 |
PPP3CA
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
283 |
PPP3CB
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
284 |
PPP3CB
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
285 |
PPP3CC
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
286 |
PPP3CC
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
287 |
PPP3R1
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
288 |
PPP3R1
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
289 |
PPP3R2
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
290 |
PPP3R2
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
291 |
CHRNA9
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
292 |
PRKAA1
| 20件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| 25件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 |
293 |
PRKAA2
| 20件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| 25件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 |
294 |
CACNA2D3
| 7件: MAPK signaling pathway MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
295 |
CACNA2D3
| 7件: MAPK signaling pathway MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02716
D02716
|
Pregabalin
| 5件: 13 13, 36, 46, 70, 298 |
296 |
PSENEN
| 2件: Notch signaling pathway Notch signaling pathway, Alzheimer disease | D09010
D09010
|
Tarenflurbil
| 1件: 13 13 |
297 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
298 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
299 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
300 |
PSEN1
| 6件: Wnt signaling pathway Wnt signaling pathway, Notch signaling pathway, Neurotrophin signaling pathway, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Human papillomavirus infection | D09010
D09010
|
Tarenflurbil
| 1件: 13 13 |
301 |
PSMB5
| 8件: Proteasome Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases | D03150
D03150
|
Bortezomib
| 17件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331 |
302 |
PSMB5
| 8件: Proteasome Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases | D10130
D10130
|
Ixazomib
| 5件: 13 13, 16, 28, 51, 61 |
303 |
RGMA
| 2件: TGF-beta signaling pathway TGF-beta signaling pathway, Axon guidance | D11355
D11355
|
Elezanumab
| 1件: 13 13 |
304 |
CHRNA10
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 2件: 13 13, 84 |
305 |
PTGDR
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01128
D01128
|
Ramatroban
| 1件: 13 13 |
306 |
PTGIR
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
307 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00109
D00109
|
Acetylsalicylic acid
| 14件: 13 13, 22, 46, 49, 51, 58, 64, 86, 97, 113, 158, 210, 231, 251 |
308 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00118
D00118
|
Naproxen
| 4件: 13 13, 46, 107, 271 |
309 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00126
D00126
|
Ibuprofen
| 7件: 13 13, 46, 65, 107, 113, 271, 299 |
310 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00217
D00217
|
Acetaminophen
| 15件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337 |
311 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00330
D00330
|
Flurbiprofen
| 3件: 13 13, 21, 46 |
312 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D07816
D07816
|
Diclofenac
| 5件: 13 13, 34, 46, 78, 271 |
313 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00109
D00109
|
Acetylsalicylic acid
| 14件: 13 13, 22, 46, 49, 51, 58, 64, 86, 97, 113, 158, 210, 231, 251 |
314 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00118
D00118
|
Naproxen
| 4件: 13 13, 46, 107, 271 |
315 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00126
D00126
|
Ibuprofen
| 7件: 13 13, 46, 65, 107, 113, 271, 299 |
316 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00217
D00217
|
Acetaminophen
| 15件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337 |
317 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00330
D00330
|
Flurbiprofen
| 3件: 13 13, 21, 46 |
318 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D07816
D07816
|
Diclofenac
| 5件: 13 13, 34, 46, 78, 271 |
319 |
RARA
| 5件: Th17 cell differentiation Th17 cell differentiation, Estrogen signaling pathway, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia | D06543
D06543
|
Vitamin A
| 3件: 13 13, 53, 90 |
320 |
RARB
| 4件: Pathways in cancer Pathways in cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer | D06543
D06543
|
Vitamin A
| 3件: 13 13, 53, 90 |
321 |
RRM1
| 6件: Purine metabolism Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D01370
D01370
|
Cladribine
| 3件: 11 11, 13, 94 |
322 |
RRM1
| 6件: Purine metabolism Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D07966
D07966
|
Fludarabine
| 20件: 11 11, 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326 |
323 |
RRM2
| 7件: Purine metabolism Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, p53 signaling pathway | D00341
D00341
|
Hydroxyurea
| 8件: 3 3, 13, 19, 20, 65, 85, 86, 284 |
324 |
RXRA
| 17件: PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Bile secretion, Hepatitis C, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
325 |
RXRB
| 13件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
326 |
RXRG
| 13件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
327 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00252
D00252
|
Carbamazepine
| 2件: 13 13, 231 |
328 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00354
D00354
|
Lamotrigine
| 5件: 13 13, 34, 38, 114, 144 |
329 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00358
D00358
|
Lidocaine
| 12件: 13 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256 |
330 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00512
D00512
|
Phenytoin
| 1件: 13 13 |
331 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00533
D00533
|
Oxcarbazepine
| 1件: 13 13 |
332 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D08127
D08127
|
Lidocaine
| 12件: 13 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256 |
333 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D08458
D08458
|
Quinidine
| 1件: 13 13 |
334 |
SCN2A
| 1件: Taste transduction Taste transduction | D00252
D00252
|
Carbamazepine
| 2件: 13 13, 231 |
335 |
SCN2A
| 1件: Taste transduction Taste transduction | D00354
D00354
|
Lamotrigine
| 5件: 13 13, 34, 38, 114, 144 |
336 |
|